|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fecal microbiota transplantation as novel therapy in gastroenterology:A systematic review显示文摘AIM:To study the clinical efficacy and safety of Fecal microbiota transplantation(FMT).We systematically reviewed FMT used as clinical therapy.METHODS:We searched MEDLINE,EMBASE,the Cochrane Library and Conference proceedings from inception to July,2013.Treatment effect of FMT was calculated as the percentage of patients who achieved clinical improvement per patient category,on an intention-to-treat basis.RESULTS:We included 45 studies;34 on Clostridium difficile-infection(CDI),7 on inflammatory bowel disease,1 on metabolic syndrome,1 on constipation,1 on pouchitis and 1 on irritable bowel syndrome(IBS).In CDI 90% resolution of diarrhea in 33 case series(n = 867) was reported,and 94% resolution of diarrhea after repeated FMT in a randomized controlled trial(RCT)(n = 16).In ulcerative colitis(UC) remission rates of 0% to 68% were found(n = 106).In Crohn's disease(CD)(n = 6),no benefit was observed.In IBS,70% improvement of symptoms was found(n = 13).100% Reversal of symptoms was observed in constipation(n = 3).In pouchitis,none of the patients(n = 8) achieved remission.One RCT showed significant improvement of insulin sensitivity in metabolic syndrome(n = 10).Serious adverse events were rare.CONCLUSION:FMT is highly effective in CDI,and holds promise in UC.As for CD,chronic constipation,pouchitis and IBS data are too limited to draw conclusions.FMT increases insulin sensitivity in metabolic syndrome. | Noortje G Rossen John K Mac Donald Elisabeth M de Vries Geert R D'Haens Willem M de Vos Erwin G Zoetendal Cyriel Y Ponsioen | 2015 | World Journal of Gastroenterology2015，21，17： | 41 |
| 2 | AGNP精神科治疗药物监测共识指南:2011显示文摘治疗药物监测(Therapeutic drug monitoring,TDM),如通过定量测定血清或血浆药物浓度指导用药剂量优化,已经成为对患者进行精神药物治疗的很有价值的工具。在患者用药依从性难以判断、药物耐受性不佳、治疗剂量下无效以及可能存在药代动力学药物-药物相互作用等情况下,测定药物浓度是很有用的。在精神科,有可能明显获益于TDM的主要患者群体包括儿童、孕妇、老年患者、智力障碍患者、涉及司法的患者、已知或怀疑携带药代动力学相关基因变异的患者,以及合并躯体疾病影响药代动力学的患者。然而,只有将TDM充分整合到临床治疗过程中去,才能发挥其优化药物治疗的潜在优势。为了促进TDM的合理应用,神经精神药理学与药物精神病学协会(Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie,AGNP)的TDM专家组在2004年发表了精神药物治疗药物监测指南。之后,随着知识不断更新,又有许多可能需要进行TDM的新药上市。因此,本次更新将神经精神药物的种类扩展到了128种,并将其TDM必要性划分为从'强烈推荐'到'可能有用'的四个等级。经过大量细致且全面的文献检索与分门别类的汇总整理,将基于循证医学理念的'治疗参考浓度范围'和'剂量相关参考浓度范围'呈现给大家。本共识指南引入了'实验室警戒浓度'的新概念,即实验室需要马上告知治疗医生的药物浓度上限。本共识指南还给出了诸如药物作为细胞色素P450酶的底物和抑制剂的性质,代谢物与母药浓度比值的常见范围,以及与结果解释相关的内容,还提供了何时将TDM与遗传药理学检测相结合的建议。遵循本指南,有助于改善许多患者精神药物治疗的效果,特别是那些存在药代动力学异常的患者。TDM是一门交叉学科,有时针对看起来不一致的数据,需要多学科坦诚地讨论,只有这样,患者才能从这种合作中获益。 | Hiemke C Baumann P Bergemann N Conca A Dietmaier O Egberts K Fric M Gerlach M Greiner C Gründer G Haen E Havemann-Reinecke U Jaquenoud Sirot E Kirchherr H Laux G Lutz UC Messer T Müller MJ Pfuhlmann B Rambeck B Riederer P Schoppek B Stingl J Uhr M Ulrich S Waschgler R Zernig G 李文标(译) 果伟(译) 阮灿军(译) 贺静(译) 汤宜朗(审校) 王传跃(审校) | 2016 | 实用药物与临床2016，19，10： | 37 |
| 3 | Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis显示文摘 | William J. Sandborn Gert van Assche Walter Reinisch Jean–Frederic Colombel Geert D’Haens Douglas C. Wolf Martina Kron Mary Beth Tighe Andreas Lazar Roopal B. Thakkar | 2012 | Gastroenterology2012，，2： | 9 |
| 4 | Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients显示文摘miRNAs 为尖锐心肌的梗塞(AMI ) 作为潜在的 biomarkers 显示出诺言。然而,当前的使用的量的即时 PCR (qRT-PCR ) 完全为 nucleic 酸的相对表示允许,它产生日常可变性,它限制了把 miRNAs 用作 biomarkers 的有效性。在这研究,我们探索了技术质量和一种新技术的诊断潜力,基于薄片的数字 PCR,在确定在有 AMI 和 ischaemia-reperfusion 损害(I/R ) 的病人的 miRNAs。在合成 C.elegans-miR-39 的一个冲淡系列,基于薄片的数字 PCR 与 qRT-PCR 相比显示了变化(8.9% 对 46.3%) 和察觉(0.2 copies/L 对 1.1 copies/L ) 的更低的限制的一个更低的系数。在从有圣举起心肌的梗塞( STEMI )的 24 个病人和有稳定的冠的动脉疾病( CAD )的 20 个病人镇定的浆液在经皮的冠的干预(一种总线标准)以后的病人,我们使用了 qRT-PCR 和多路的基于薄片的数字 PCR 确定他们在优先的研究在 AMI 被验证了的 miRNA-21 和 miRNA-499 的浆液层次。在 STEMI, I/R 损害经由圣片断分辨率(ST-R ) 的测量被估计。基于薄片的数字 PCR 处于在稳定的 CAD 和 STEMI 组之间的 miR-21 层次的差别揭示了统计意义(118.8 copies/L 对 59 copies/L;P=0.0300 ) ,而 qRT-PCR 是不能的到达意义(136.4 copies/L 对 122.8 copies/L;P=0.2273 ) 。为 miR-499 层次,基于薄片的数字 PCR 和 qRT-PCR 揭示了稳定的 CAD 和 STEMI 组之间的统计上重要的差别(2 copies/L 对 8.5 copies/L, P=0.0011;0 copies/L 对 19.4 copies/L;P < 0.0001 ) 。在 miR-21/499 层次和 ST-R 之间没有协会一种总线标准以后。我们的结果证明基于薄片的数字 PCR 展出优异技术质量和诺言是一个优异方法因为确定的 miRNA 在发行量铺平,它可以为直接确定成为一个更精确、可再现的方法 miRNAs,特别地为在大多中心的使用临床的试用。 | Samuel ROBINSON Marie FOLLO David HAENE Maximilian MAULER Daniela STALLMANN Lukas Andreas HEGER Thomas HELBING Daniel DUERSCHMIED Karlheinz PETER Christoph BODE Ingo AHRENS Marcus HORTMANN | 2018 | Acta Pharmacologica Sinica2018，39，7： | 5 |
| 5 | Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial显示文摘 | Geert D’Haens Filip Baert Gert van Assche Philip Caenepeel Philippe Vergauwe Hans Tuynman Martine De Vos Sander van Deventer Larry Stitt Allan Donner Severine Vermeire Frank J Van De Mierop Jean-Charles R Coche Janneke van der Woude Thomas Ochsenkühn Ad A | 2008 | The Lancet2008，，9613： | 5 |
| 6 | Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn’s Disease: Data From the EXTEND Trial显示文摘 | Paul Rutgeerts Gert Van Assche William J. Sandborn Douglas C. Wolf Karel Geboes Jean–Frédéric Colombel Walter Reinisch Ashish Kumar Andreas Lazar Anne Camez Kathleen G. Lomax Paul F. Pollack Geert D’Haens | 2012 | Gastroenterology2012，，5： | 4 |
| 7 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management显示文摘 | Axel Dignass James O. Lindsay Andreas Sturm Alastair Windsor Jean-Frederic Colombel Mathieu Allez Gert D’Haens André D’Hoore Gerassimos Mantzaris Gottfried Novacek Tom ?resland Walter Reinisch Miquel Sans Eduard Stange Severine Vermeire Simon Travis Gert | 2012 | Journal of Crohn’s and Colitis2012，，10： | 4 |
| 8 | European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease显示文摘 | J.F. Rahier S. Ben-Horin Y. Chowers C. Conlon P. De Munter G. D’Haens E. Domènech R. Eliakim A. Eser J. Frater M. Gassull M. Giladi A. Kaser M. Lémann T. Moreels A. Moschen R. Pollok W. Reinisch M. Schunter E.F. Stange H. Tilg G. Van Assche N. Viget B. Vu | 2009 | Journal of Crohn’s and Colitis2009，，2： | 3 |
| 9 | The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations显示文摘 | Gert Van Assche Axel Dignass Walter Reinisch C. Janneke van der Woude Andreas Sturm Martine De Vos Mario Guslandi Bas Oldenburg Iris Dotan Philippe Marteau Alessandro Ardizzone Daniel C. Baumgart Geert D’Haens Paolo Gionchetti Francisco Portela Boris Vuce | 2009 | Journal of Crohn’s and Colitis2009，，1： | 3 |
| 10 | <ce:link locator='fx1'/> A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis显示文摘 | Geert D’Haens William J. Sandborn Brian G. Feagan Karel Geboes Stephen B. Hanauer E. Jan Irvine Marc Lémann Philippe Marteau Paul Rutgeerts Jurgen Sch?lmerich Lloyd R. Sutherland | 2007 | Gastroenterology2007，，2： | 2 |
| 11 | Novel Targets for Inflammatory Bowel Disease Therapeutics显示文摘 | Mark L?wenberg Geert D’Haens | 2013 | Current Gastroenterology Reports2013，，2： | 2 |
| 12 | A simple classification of Crohn’s disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998显示文摘 | ChristophGasche JurgenScholmerich JornBrynskov GeertD’Haens Stephen B.Hanauer E. JanIrvine Derek P.Jewell DanielRachmilewitz David B.Sachar William J.Sandborn Lloyd R.Sutherland | 2007 | Inflamm Bowel Dis2007，，1： | 2 |
| 13 | Future directions in inflammatory bowel disease management显示文摘 | Geert R. D’Haens R. Balfour Sartor Mark S. Silverberg Joel Petersson Paul Rutgeerts | 2014 | Journal of Crohn’s and Colitis2014，，： | 2 |
| 14 | Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Had Failed显示文摘 | Bruce E. Sands Brian G. Feagan Paul Rutgeerts Jean-Frédéric Colombel William J. Sandborn Richmond Sy Geert D’Haens Shomron Ben-Horin Jing Xu Maria Rosario Irving Fox Asit Parikh Catherine Milch Stephen Hanauer | 2014 | Gastroenterology2014，，： | 2 |
| 15 | IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010 – Inflammatory bowel disease task force meeting显示文摘 | Daniel C.Baumgart Charles N.Bernstein ZaighamAbbas Jean F.Colombel Andrew S.Day GeertD’Haens IrisDotan Khean L.Goh ToshifumiHibi Richard A.Kozarek Eamonn M.M.Quigley WalterReinisch Bruce E.Sands Jose D.Sollano A. HillarySteinhart FlávioSteinwurz Morten H. | 2011 | Inflamm Bowel Dis2011，，2： | 2 |
| 16 | Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: A randomized, double-blind, placebo-controlled trial显示文摘 | Paul Rutgeerts Gert van Assche Séverine Vermeire Geert D’Haens Filip Baert Maja Noman Isolde Aerden Gert de Hertogh Karel Geboes Martin Hiele Andre D’Hoore Freddy Penninckx | 2005 | Gastroenterology2005，，4： | 2 |
| 17 | European evidence-based Consensus on the management of ulcerative colitis: Current management显示文摘 | S.P.L. Travis E.F. Stange M. Lémann T. ?resland W.A. Bemelman Y. Chowers J.F. Colombel G. D'Haens S. Ghosh P. Marteau W. Kruis N.J.McC. Mortensen F. Penninckx M. Gassull | 2008 | Journal of Crohn’s and Colitis2008，，1： | 2 |
| 18 | Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn’s Disease: Results From the CHARM Study显示文摘 | Brian G. Feagan Remo Panaccione William J. Sandborn Geert R. D’Haens Stefan Schreiber Paul J. Rutgeerts Edward V. Loftus Kathleen G. Lomax Andrew P. Yu Eric Q. Wu Jingdong Chao Parvez Mulani | 2008 | Gastroenterology2008，，5： | 2 |
| 19 | Adalimumab for Crohn’s disease: Long-term sustained benefit in a population-based cohort of 438 patients显示文摘 | Charlotte P. Peters Emma J. Eshuis Florien M. Toxopeüs Merel E. Hellemons Jeroen M. Jansen Geert R.A.M. D’Haens Paul Fockens Pieter C.F. Stokkers Hans A.R.E. Tuynman Adriaan A. van Bodegraven Cyriel Y. Ponsioen | 2014 | Journal of Crohn’s and Colitis2014，，： | 2 |
| 20 | <ce:link locator='fx1'/> A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis显示文摘 | Geert D'Haens William J. Sandborn Brian G. Feagan Karel Geboes Stephen B. Hanauer E. Jan Irvine Marc Lémann Philippe Marteau Paul Rutgeerts Jurgen Sch?lmerich Lloyd R. Sutherland | 2007 | Gastroenterology2007，，2： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员